Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods

Thrombosis Research

Volumn 133, Issue 5, 2014, Pages 811-816

  Kovács, Emese G ^a   Katona, Éva ^a   Bereczky, Zsuzsanna ^a   Homoródi, Nóra ^a   Balogh, László ^a   Tóth, Eszter ^a   Péterfy, Hajna ^b   Kiss, Róbert G ^c   Édes, István ^a   Muszbek, László ^a,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Diagnosticum Ltd   (Hungary)

^c State Health Center   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

aspirin; aspirin resistance; platelet aggregation; platelet secretion; reference method; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 1; PTGS1 PROTEIN, HUMAN;

ADULT; BLOOD; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HOSPITAL LABORATORY; HUMAN; MALE; MIDDLE AGED; REFERENCE VALUE; THROMBOCYTE; YOUNG ADULT;

ADULT; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LABORATORIES, HOSPITAL; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; YOUNG ADULT;

EID: 84898803325     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.10.008     Document Type: Article

References (41)

1. J.W. Eikelboom, J. Hirsh, F.A. Spencer, T.P. Baglin, and J.I. Weitz Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 9th ed. Chest 141 2012 e89S 119S
2. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
3. Collaboration AT Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
4. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
5. P.O. Vandvik, A.M. Lincoff, J.M. Gore, D.D. Gutterman, F.A. Sonnenberg, and P. Alonso-Coello et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e637S e668S
6. S. Coccheri Antiplatelet therapy: controversial aspects Thromb Res 129 2012 225 229
7. D.L. Simmons, R.M. Botting, and T. Hla Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 2004 387 437
8. R.J. Kulmacz, W.A. van der Donk, and A.L. Tsai Comparison of the properties of prostaglandin H synthase-1 and -2 Prog Lipid Res 42 2003 377 404
9. L. Toth, L. Muszbek, and I. Komaromi Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations J Mol Graph Model 40 2013 99 109
10. C. Patrono, and B. Rocca Aspirin, 110 years later J Thromb Haemost 7 Suppl. 1 2009 258 261
11. J.M. Sweeny, D.A. Gorog, and V. Fuster Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements Nat Rev Cardiol 6 2009 273 282
12. D.A. Gorog, J.M. Sweeny, and V. Fuster Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol 6 2009 365 373
13. J.L. Mehta, and B. Mohandas Aspirin resistance: Fact or fiction? A point of view World J Cardiol 2 2010 280 288
14. J. Grinstein, and C.P. Cannon Aspirin resistance: current status and role of tailored therapy Clin Cardiol 35 2012 673 681
15. C. Kasmeridis, S. Apostolakis, and G.Y. Lip Aspirin and aspirin resistance in coronary artery disease Curr Opin Pharmacol 13 2013 242 250
16. S. Raichand, D. Moore, R.D. Riley, M. Lordkipanidze, J. Dretzke, and J. O'Donnell et al. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease Syst. Rev. 2 2013 16
17. H.C. Arazi, D.G. Doiny, R.S. Torcivia, H. Grancelli, S.V. Waldman, and C. Nojek et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery Interact Cardiovasc Thorac Surg 10 2010 863 867
18. E.L. Grove, A.M. Hvas, and S.D. Kristensen Immature platelets in patients with acute coronary syndromes Thromb Haemost 101 2009 151 156
19. P. Henry, A. Vermillet, B. Boval, C. Guyetand, T. Petroni, and J.G. Dillinger et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb Haemost 105 2011 336 344
20. B. Rocca, F. Santilli, D. Pitocco, L. Mucci, G. Petrucci, and E. Vitacolonna et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes J Thromb Haemost 10 2012 1220 1230
21. G.J. Roth, and P.W. Majerus The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein J Clin Invest 56 1975 624 632
22. J.W. Burch, N. Stanford, and P.W. Majerus Inhibition of platelet prostaglandin synthetase by oral aspirin J Clin Invest 61 1978 314 319
23. E.G. Kovacs, E. Katona, Z. Bereczky, N. Homorodi, L. Balogh, and E. Toth et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals Thromb Res 131 2013 320 324
24. M.D. Linden, H. Tran, R. Woods, and A. Tonkin High platelet reactivity and antiplatelet therapy resistance Semin Thromb Hemost 38 2012 200 212
25. G. Renda, M. Zurro, G. Malatesta, B. Ruggieri, and R. De Caterina Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance Haematologica 95 2010 2095 2101
26. J.B. Andersen, B. Koch, T.H. Nielsen, D. Sorensen, M. Hansen, and O. Nybroe et al. Surface motility in Pseudomonas sp. DSS73 is required for efficient biological containment of the root-pathogenic microfungi Rhizoctonia solani and Pythium ultimum Microbiology 149 2003 37 46
27. T.J. Kunicki, S.A. Williams, D.R. Salomon, P. Harrison, P. Crisler, and P. Nakagawa et al. Genetics of platelet reactivity in normal, healthy individuals J Thromb Haemost 7 2009 2116 2122
28. M. Eugster, and W.H. Reinhart The influence of the haematocrit on primary haemostasis in vitro Thromb Haemost 94 2005 1213 1218
29. E.J. Favaloro The utility of the PFA-100 in the identification of von Willebrand disease: a concise review Semin Thromb Hemost 32 2006 537 545
30. H.J. Weiss, and B. Lages The response of platelets to epinephrine in storage pool deficiency-evidence pertaining to the role of adenosine diphosphate in mediating primary and secondary aggregation Blood 72 1988 1717 1725
31. M. McCabe White, and L.K. Jennings Platelet Protocols 1999 Academic Press New York
32. R. Fitzgerald, and M. Pirmohamed Aspirin resistance: effect of clinical, biochemical and genetic factors Pharmacol Ther 130 2011 213 225
33. P.M. Ho, J.A. Spertus, F.A. Masoudi, K.J. Reid, E.D. Peterson, and D.J. Magid et al. Impact of medication therapy discontinuation on mortality after myocardial infarction Arch Intern Med 166 2006 1842 1847
34. K.A. Schwartz, D.E. Schwartz, K. Barber, M. Reeves, and A.C. De Franco Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients J Transl Med 6 2008 46
35. A.D. Michelson, M. Cattaneo, J.W. Eikelboom, P. Gurbel, K. Kottke-Marchant, and T.J. Kunicki et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance J Thromb Haemost 3 2005 1309 1311
36. A.A. Weber, K.C. Zimmermann, J. Meyer-Kirchrath, and K. Schror Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance Lancet 353 1999 900
37. M.K. Halushka, and P.V. Halushka Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105 2002 1620 1622
38. B. Rocca, P. Secchiero, G. Ciabattoni, F.O. Ranelletti, L. Catani, and L. Guidotti et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634 7639
39. S. Riondino, E. Trifiro, L. Principessa, S. Mascioletti, L. Di Renzo, and C. Gaudio et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production Thromb Res 122 2008 359 365
40. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, and A. De Salvo et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb Res 17 1980 317 327
41. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, and M.V. Huisman Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 2007 1593 1599